Immunic, Inc. Executes 1-for-10 Reverse Stock Split to Enhance Market Position

Overview of Immunic, Inc.

Immunic, Inc., a notable player in the biotechnology space, is primarily focused on creating innovative oral therapies for various neurologic diseases. The company's advancements are noteworthy as it progresses towards late-stage clinical trials, addressing significant health challenges such as relapsing multiple sclerosis. As the landscape of biotechnology evolves, Immunic has demonstrated its commitment to developing effective treatments that can transform patient care.

Recent Announcement on Stock Split

On April 23, 2026, Immunic disclosed that it would initiate a 1-for-10 reverse stock split effective at 12:01 A.M. ET on April 27, 2026. This strategic move has been approved by shareholders during a special meeting held on April 14, 2026. The decision to implement a reverse stock split comes at a critical time as the company seeks to fulfill obligations under a securities purchase agreement established with institutional investors.

Details of the Stock Split

This reverse stock split will see Immunic consolidate its shares, transforming every ten shares of common stock into one. As a result, the total number of outstanding shares will decrease from approximately 136 million to about 13.6 million. Consequently, this action is designed to enhance the company's stock price, aligning with its obligations and potentially attracting more investors. Importantly, the stock will continue trading on the Nasdaq Capital Market under the symbol IMUX, but the trading will reflect the adjusted ratio starting April 27, 2026.

In connection to the stock split, the company will issue a new CUSIP number (4525EP200) for the adjusted common shares. Shareholders should note that fractional shares will not be issued; instead, they will receive cash equivalent to their proportionate share of the total proceeds from sales of such fractional shares, ensuring that all stockholders are treated fairly during this transition.

Long-term Objectives and Future Implications

The reverse stock split is seen as a move to bolster Immunic’s financial future, facilitating its growth and ensuring compliance with investor agreements. Furthermore, it will not alter the authorized shares’ count or change the par value of the common stock. Stock options and similar securities will also undergo proportional adjustments to reflect the reverse split. This adjustment aims to maintain value for existing shareholders, ensuring the market position of Immunic is not negatively impacted.

Clinical Advancements

Immunic’s lead project, vidofludimus calcium (IMU-838), is currently undergoing Phase 3 clinical trials, with results anticipated by the end of 2026. This therapy showcases promise as it integrates neuroprotective effects and anti-inflammatory properties, tackling not just multiple sclerosis but also offering insights into potential treatments for chronic inflammatory and neurodegenerative diseases.

Conclusion

In summary, Immunic, Inc.'s decision to execute a reverse stock split reinforces the company's commitment to improving its financial standing and operational capacity. By aligning with investor expectations and enhancing market performance, Immunic is well-positioned for future growth within the competitive biotechnology sector. As they continue to advance their clinical trials and develop innovative therapies, stakeholders and potential investors will be watching closely to see how this strategic decision plays out in the coming months.